Sucralfate
Al8(OH)16(C12H14O35S8) [Al(OH)3]x [H2O]y
Sucralfate is the basic aluminium salt of sucrose octasulfate (SOS). The therapeutic effect of Sucralfate in gastric complaints is based on an increase in the protective mechanisms of the mucous membranes in the stomach and duodenum against exogenous and endogenous aggressors.
The cytoprotective action of Sucralfate includes the neutralization of acid, the selective formation of a protective layer over eroded surface areas, specific protection of lesions and adsorption of pepsin and bile acids, resulting in inhibition of peptic activity.
Sucralfate Powder S 215, S 225 and S 235
Sucralfate S 215 powder is suitable for use in tablet formulations. Sucralfate S225 is a milled powder ideal for use in soft tablet and candy formulations or for powder mixtures intended for resuspending (powder sachets). Sucralfate S 235 is available for direct compressible tablet formulations.
| Type | S 215 | S 225 | S 235 |
| Assay Al | 15,5 - 18,5 [%] | 15,5 - 18,5 [%] | 15,5 - 18,5 [%] |
| Assay SOS | 30,0 - 38,0 [%] | 30,0 - 38,0 [%] | 30,0 - 38,0 [%] |
| Density (tapped) | 0,55 - 0,75 [g/ml] | 0,30 - 0,48 [g/ml] | 0,6 - 0,8 [g/ml] |
| d50 | 30 - 70 [µm] | 3 - 5 [µm] | 90 - 130 [µm] |
| Pharmacopoeia | USP, PhEur | USP, PhEur | USP, PhEur |
Sucralfate Suspension
Sucralfate S 611 and S625 are suspensions with an active content of 30% with a temporary preservation with p- and m-ester. S611 is ideal for use in liquid antacid formulations while S625 is a very fine suspension with a low particle size.
Sucralfate Suspension S601 is used in medical devices and is temporarily preserved with hydrogen peroxide.
With our deep knowledge of Sucralfate and our manufacturing authorisation for bulk formulations we are able to manufacture Sucralfate final products. Together with our long-term partners we can thus offer full service for Sucralfate suspensions.
| Type | S601 | S611 | S625 |
| Assay | > 4,8 [%] | 4,7 - 6,0 [%] | 4,7 - 6,0 [%] |
| Assay SOS | > 8,6 [%] | 8,3 - 13,4 [%] | 9,1 - 12,3 [%] |
| Particle size | d50: 5 - 10 µm | d50: 5 - 10 µm | d50: 3 - 5 µm min 85% < 10 µm |
| Pharmacopoeia | USP | USP |